Answers are grounded in this paper and cite their sources.
Case report highlights delayed hydroxyurea initiation, indicating gaps in adult sickle cell anaemia management.
Objectives: Background: Sickle Cell Anaemia (SCA) is a lifelong haemoglobinopathy marked by chronic haemolysis, recurrent vaso-occlusive crises (VOCs), and progressive organ damage. Hydroxyurea is a well-established disease-modifying therapy; however, its use in adults remains inconsistent, particularly in regions with limited access to specialised care. Case Presentation: We describe a 35-year-old Saudi woman with homozygous SCA who presented with acute back and limb pain unresponsive to standard analgesia. She reported frequent admissions and transfusions but had never received hydroxyurea. On admission, she was tachypneic with oxygen desaturation (SpO₂ 80%) and borderline hypotension. Laboratory evaluation revealed normocytic anaemia (Hb 8.2 g/dL), elevated lactate dehydrogenase (317 U/L), reticulocytosis (6.12%), and severe vitamin D deficiency (7 ng/mL). Hydroxyurea (500 mg/day) was initiated in conjunction with folic acid and vitamin D supplementation. At the two-week follow-up, her pain score improved from 6/10 to 3/10, her energy levels increased, oxygen saturation stabilised, and laboratory monitoring demonstrated reduced haemolysis with stable haemoglobin levels. Discussion and conclusion: This case illustrates how delayed initiation of hydroxyurea represents a missed therapeutic opportunity in adult SCA, particularly among women beyond childbearing age. The timely use of hydroxyurea, combined with the correction of comorbidities such as vitamin D deficiency, can improve quality of life. Standardised pathways and systematic reassessment are urgently needed to ensure consistent adult SCA care.
No takes yet. Share an insight, caveat, or question.
Saeed Kabrah (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: